drugset
drugset / Trial / NCT05187858

A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors

NCT05187858 ↗

Phase 1 Completed 15 enrolled Lupin Ltd.
NaSequentialOpen-labelTreatment

Summary

This is a Phase I, open-label, dose escalation study of LNP3794 (BI3011441) in subjects with NRAS/KRAS mutated advanced or metastatic refractory solid tumors. The purpose of this study is to evaluate the safety/tolerability, pharmacokinetic and pharmacodynamic profile of the orally administered LNP3794 (BI3011441) as monotherapy at selected dose levels.

Timeline

Start
2020-09-22
Primary completion
2022-02-23
Completion
2022-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject LNP3794 Unknown — Oral

Indications

No indication recorded.